A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Byers L. A., Navarro A., Schaefer E., Johnson M., Ozguroglu M., Han J., ...More

CLINICAL LUNG CANCER, vol.22, no.6, pp.531-540, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.1016/j.cllc.2021.04.005
  • Journal Name: CLINICAL LUNG CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.531-540
  • Keywords: Checkpoint kinase 1 inhibitor, Relapsed, Refractory, Small cell lung cancer, Pharmacokinetics, Biomarker, 2ND-LINE TREATMENT, TOPOTECAN, CYCLOPHOSPHAMIDE, VINCRISTINE, CISPLATIN
  • Istanbul University Affiliated: Yes

Abstract

Patients with extensive-stage small-cell lung cancer (ED-SCLC) need improved outcomes in the relapsed/refractory setting. This phase II study evaluated the safety and efficacy of prexasertib, a checkpoint kinase 1 inhibitor, in platinum-sensitive and platinum-refractory ED-SCLC. Prexasertib demonstrated response rates of 5.2% in platinum-sensitive and 0% in platinum-refractory ED-SCLC. Prexasertib did not show prespecified efficacy as monotherapy in ED-SCLC.